-
3
-
-
0036850282
-
Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility
-
Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552-58
-
(2002)
Trends Biochem. Sci.
, vol.27
, pp. 552-558
-
-
Turton, K.1
Chaddock, J.A.2
Acharya, K.R.3
-
4
-
-
33748271738
-
Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
-
Brin MF. 1997. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 20:S146-S168
-
(1997)
Muscle Nerve
, vol.20
-
-
Brin, M.F.1
-
5
-
-
0032145932
-
Botulism in the United States: A clinical and epidemiologic review
-
Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 129:221-28
-
(1998)
Ann. Intern. Med.
, vol.129
, pp. 221-228
-
-
Shapiro, R.L.1
Hatheway, C.2
Swerdlow, D.L.3
-
6
-
-
0025857556
-
Therapeutic uses of botulinum toxin
-
Jankovic J, Brin MF. 1991. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324:1186-94
-
(1991)
N. Engl. J. Med.
, vol.324
, pp. 1186-1194
-
-
Jankovic, J.1
Brin, M.F.2
-
7
-
-
0000810225
-
Botulinum toxin: Historical perspective and potential new indications
-
Jankovic J, Brin ME. 1997. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 20:S129-S145
-
(1997)
Muscle Nerve
, vol.20
-
-
Jankovic, J.1
Brin, M.E.2
-
8
-
-
0034758711
-
Review of botulinum toxin type a and its clinical applications in migraine headache
-
Silberstein SD. 2001. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin. Pharmacother. 2:1649-54
-
(2001)
Expert Opin. Pharmacother.
, vol.2
, pp. 1649-1654
-
-
Silberstein, S.D.1
-
9
-
-
0036841338
-
Considering the immune response to botulinum toxin
-
Critchfield J. 2002. Considering the immune response to botulinum toxin. Clin. J. Pain 18:S133-S141
-
(2002)
Clin. J. Pain
, vol.18
-
-
Critchfield, J.1
-
10
-
-
0029977787
-
Botulinum toxin therapy, immunologic resistance, and problems with available materials
-
Borodic G, Johnson E, Goodnough M, et al. 1996. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26-29
-
(1996)
Neurology
, vol.46
, pp. 26-29
-
-
Borodic, G.1
Johnson, E.2
Goodnough, M.3
-
11
-
-
0031955695
-
Current concepts on the clinical features, aetioogy and management of idiopathic cervical dystonia
-
Dauer WT, Burke RE, Greene P, et al. 1998. Current concepts on the clinical features, aetioogy and management of idiopathic cervical dystonia. Brain 121:547-60
-
(1998)
Brain
, vol.121
, pp. 547-560
-
-
Dauer, W.T.1
Burke, R.E.2
Greene, P.3
-
12
-
-
0027421580
-
Botulinum antibodies in dystonic patients treated with type a botulinum toxin: Frequency and significance
-
Zuber M, Sebald M, Bathien N, et al. 1995. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715-18
-
(1995)
Neurology
, vol.43
, pp. 1715-1718
-
-
Zuber, M.1
Sebald, M.2
Bathien, N.3
-
13
-
-
0028345811
-
Development of resistance to botulinum toxin type a in patients with torticollis
-
Greene P, Fahn S, Diamond B. 1994. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9:213-17
-
(1994)
Mov. Disord.
, vol.9
, pp. 213-217
-
-
Greene, P.1
Fahn, S.2
Diamond, B.3
-
14
-
-
0028803612
-
Response and immunoresistance to botulinum toxin injections
-
Jankovic J, Schwartz K. 1995. Response and immunoresistance to botulinum toxin injections. Neurology 45:1743-46
-
(1995)
Neurology
, vol.45
, pp. 1743-1746
-
-
Jankovic, J.1
Schwartz, K.2
-
15
-
-
1542276451
-
Botulinum toxin type B in antibody-induced botulinum toxin type a therapy failure
-
Abstr.
-
Dressler DW, Bigalke H, Benecke R. 2003. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Neurology 60:A465-A466 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Dressler, D.W.1
Bigalke, H.2
Benecke, R.3
-
16
-
-
26144434854
-
Development of a new low molecular weight botulinum type a neurotoxin preparation for treating muscle hyperactivity
-
Abstr.
-
Sakamoto T, Asanuma K, Kaji R, et al. 2003. Development of a new low molecular weight botulinum type A neurotoxin preparation for treating muscle hyperactivity. Neurology 60:A466 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Sakamoto, T.1
Asanuma, K.2
Kaji, R.3
-
17
-
-
0035076007
-
Pharmacology and immunology of botulinum toxin serotypes
-
Aoki KR. 2001. Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. 248:3-10
-
(2001)
J. Neurol.
, vol.248
, pp. 3-10
-
-
Aoki, K.R.1
-
18
-
-
0032839760
-
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system
-
Naumann M, Jost WH, Toyka KV. 1999. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch. Neurol. 56:914-16
-
(1999)
Arch. Neurol.
, vol.56
, pp. 914-916
-
-
Naumann, M.1
Jost, W.H.2
Toyka, K.V.3
-
19
-
-
0035864927
-
Botulinum toxin a for axillary hyperhidrosis (excessive sweating)
-
Heckmann M, Ceballos-Baumann AO, Plewig G, for the Hyperhidrosis Study Group. 2001. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N. Engl. J. Med. 344:488-93
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 488-493
-
-
Heckmann, M.1
Ceballos-Baumann, A.O.2
Plewig, G.3
-
20
-
-
0030710177
-
The mechanism of action of botulinum toxin type a in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site
-
Giladi N. 1997. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site. J. Neurol. Sci. 152:123-35
-
(1997)
J. Neurol. Sci.
, vol.152
, pp. 123-135
-
-
Giladi, N.1
-
21
-
-
0027312028
-
Botulinum a toxin effects on rat jaw muscle spindles
-
Filippi GM, Errico P, Santarelli R, et al. 1993. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113:400-4
-
(1993)
Acta Otolaryngol.
, vol.113
, pp. 400-404
-
-
Filippi, G.M.1
Errico, P.2
Santarelli, R.3
-
22
-
-
0029920995
-
Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection
-
Resales RL, Arimura K, Takenaga S, et al. 1996. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488-96
-
(1996)
Muscle Nerve
, vol.19
, pp. 488-496
-
-
Resales, R.L.1
Arimura, K.2
Takenaga, S.3
-
23
-
-
0033916697
-
How does botulinum toxin work?
-
Hallett M. 2000. How does botulinum toxin work? Ann. Neurol. 48:7-8
-
(2000)
Ann. Neurol.
, vol.48
, pp. 7-8
-
-
Hallett, M.1
-
24
-
-
0017701735
-
The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex
-
Wiegand H, Wellhoner HH. 1977. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch. Pharmacol. 298:235-38
-
(1977)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.298
, pp. 235-238
-
-
Wiegand, H.1
Wellhoner, H.H.2
-
25
-
-
0031731126
-
The development of BOTOX - Its history and pharmacology
-
Aoki R. 1998. The development of BOTOX - its history and pharmacology. Pain Digest 8:337-41
-
(1998)
Pain Digest
, vol.8
, pp. 337-341
-
-
Aoki, R.1
-
26
-
-
0020592243
-
Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro
-
Janicki PK, Habermann E. 1983. Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro. J. Neurochem. 41:395-402
-
(1983)
J. Neurochem.
, vol.41
, pp. 395-402
-
-
Janicki, P.K.1
Habermann, E.2
-
27
-
-
0031919375
-
The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection
-
Byrnes ML, Thickbroom GW, Wilson SA, et al. 1998. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 121:977-88
-
(1998)
Brain
, vol.121
, pp. 977-988
-
-
Byrnes, M.L.1
Thickbroom, G.W.2
Wilson, S.A.3
-
28
-
-
0033945711
-
Effects of botulinum toxin type a on intracortical inhibition in patients with dystonia
-
Gilio F, Currà A, Lorenzano C, et al. 2000. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann. Neurol. 48:20-26
-
(2000)
Ann. Neurol.
, vol.48
, pp. 20-26
-
-
Gilio, F.1
Currà, A.2
Lorenzano, C.3
-
29
-
-
0035085437
-
Botulinum toxin a in the treatment of headache syndromes and pericranial pain syndromes
-
Gobel H, Heinze A, Kuhn KH, et al. 2001. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195-99
-
(2001)
Pain
, vol.91
, pp. 195-199
-
-
Gobel, H.1
Heinze, A.2
Kuhn, K.H.3
-
30
-
-
0034895356
-
Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects
-
Borodic GE, Acquadro M, Johnson EA. 2001. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs 10:1531-44
-
(2001)
Expert Opin. Investig. Drugs
, vol.10
, pp. 1531-1544
-
-
Borodic, G.E.1
Acquadro, M.2
Johnson, E.A.3
-
31
-
-
0036840904
-
Possible mechanisms for the effects of botulinum toxin on pain
-
Arezzo JC. 2002. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain 18:S125-S132
-
(2002)
Clin. J. Pain
, vol.18
-
-
Arezzo, J.C.1
-
32
-
-
0000099458
-
Botulinum toxin type a (BTX-A) reduces inflammatory pain in the rat formalin model
-
Cui M, Aoki KR. 2000. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414
-
(2000)
Cephalalgia
, vol.20
, pp. 414
-
-
Cui, M.1
Aoki, K.R.2
-
33
-
-
0030853667
-
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
-
Lew MF, Adornato BT, Duane D, et al. 1997. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701-7
-
(1997)
Neurology
, vol.49
, pp. 701-707
-
-
Lew, M.F.1
Adornato, B.T.2
Duane, D.3
-
34
-
-
0037322405
-
Botulinum toxin a reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin
-
Kramer HH, Angerer C, Erbguth F, et al. 2003. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J. Neurol. 250:188-93
-
(2003)
J. Neurol.
, vol.250
, pp. 188-193
-
-
Kramer, H.H.1
Angerer, C.2
Erbguth, F.3
-
35
-
-
0037116179
-
Botulinum toxin a and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study
-
Blersch W, Schulte-Mattler WJ, Przywara S, et al. 2002. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J. Neurol. Sci. 205:59-63
-
(2002)
J. Neurol. Sci.
, vol.205
, pp. 59-63
-
-
Blersch, W.1
Schulte-Mattler, W.J.2
Przywara, S.3
-
36
-
-
0034603438
-
Presynaptic effects of botulinum toxin type a on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles
-
Ishikawa H, Mitsui Y, Yoshitomi T, et al. 2000. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 44:106-9
-
(2000)
Jpn. J. Ophthalmol.
, vol.44
, pp. 106-109
-
-
Ishikawa, H.1
Mitsui, Y.2
Yoshitomi, T.3
-
37
-
-
0033991246
-
Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins
-
Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-58
-
(2000)
Toxicon
, vol.38
, pp. 245-258
-
-
Welch, M.J.1
Purkiss, J.R.2
Foster, K.A.3
-
38
-
-
0042392072
-
Mechanisms of the antinociceptive effect of subcutaneous Botox®: Inhibition of peripheral and central nociceptive processing
-
Abstr.
-
Cui M, Li Z, You S, et al. 2003. Mechanisms of the antinociceptive effect of subcutaneous Botox®: inhibition of peripheral and central nociceptive processing. Arch. Pharmacol. 365:33 (Abstr.)
-
(2003)
Arch. Pharmacol.
, vol.365
, pp. 33
-
-
Cui, M.1
Li, Z.2
You, S.3
-
39
-
-
0034651211
-
Uses of botulinum toxin injection in medicine today
-
Munchau A, Bhatia KP. 2000. Uses of botulinum toxin injection in medicine today. BMJ 320:165
-
(2000)
BMJ
, vol.320
, pp. 165
-
-
Munchau, A.1
Bhatia, K.P.2
-
40
-
-
0025010020
-
Botulinum treatment of childhood strabismus
-
Scott AB, Magoon EH, McNeer KW, et al. 1990. Botulinum treatment of childhood strabismus. Ophthalmology 97:1434-38
-
(1990)
Ophthalmology
, vol.97
, pp. 1434-1438
-
-
Scott, A.B.1
Magoon, E.H.2
McNeer, K.W.3
-
41
-
-
0028569051
-
Botulinum toxin in clinical practice
-
Hughes AJ. 1994. Botulinum toxin in clinical practice. Drugs 48:888-93
-
(1994)
Drugs
, vol.48
, pp. 888-893
-
-
Hughes, A.J.1
-
43
-
-
0036840028
-
A focused review on the use of botulinum toxins for neuropathic pain
-
Argoff CE 2002. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain 6:S181
-
(2002)
Clin. J. Pain
, vol.6
-
-
Argoff, C.E.1
-
44
-
-
0036840844
-
A focused review of the use of botulinum toxins for low back pain
-
Difazio M, Jabbari B. 2002. A focused review of the use of botulinum toxins for low back pain. Clin. J. Pain 18:S155-S162
-
(2002)
Clin. J. Pain
, vol.18
-
-
Difazio, M.1
Jabbari, B.2
-
45
-
-
0036839955
-
Use of botulinum toxin in chronic whiplash-associated disorder
-
Freund BJ, Schwartz M. 2002. Use of botulinum toxin in chronic whiplash-associated disorder. Clin. J. Pain 18: S163-S168
-
(2002)
Clin. J. Pain
, vol.18
-
-
Freund, B.J.1
Schwartz, M.2
-
46
-
-
0036834143
-
Treatment of headache with botulinum toxin a - A review according to evidence-based medicine criteria
-
Evers S, Rahmann A, Vollmer-Haase J, et al. 2002. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 22:699-710
-
(2002)
Cephalalgia
, vol.22
, pp. 699-710
-
-
Evers, S.1
Rahmann, A.2
Vollmer-Haase, J.3
-
47
-
-
0036840845
-
Use of botulinum toxins for chronic headaches: A focused review
-
Loder E, Biondi D. 2002. Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain 18:S169-S176
-
(2002)
Clin. J. Pain
, vol.18
-
-
Loder, E.1
Biondi, D.2
-
48
-
-
0042369054
-
The use of botulinum toxin type a in headache treatment
-
Mathew NT, Kaup AO. 2002. The use of botulinum toxin type A in headache treatment Curr. Treatment Options Neurol. 4:365-73
-
(2002)
Curr. Treatment Options Neurol.
, vol.4
, pp. 365-373
-
-
Mathew, N.T.1
Kaup, A.O.2
-
50
-
-
0033668492
-
Botulinum toxin type a (Botox) for treatment of migraine headaches: An open-label study
-
Binder WJ, Brin MF, Blitzer A, et al. 2000. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123:669-76
-
(2000)
Otolaryngol. Head Neck Surg.
, vol.123
, pp. 669-676
-
-
Binder, W.J.1
Brin, M.F.2
Blitzer, A.3
-
51
-
-
0033917504
-
Botulinum toxin type a as a migraine preventive treatment
-
Silberstein SD, Mathew N, Saper J, et al. 2000. Botulinum toxin type A as a migraine preventive treatment. Headache 40:445-50
-
(2000)
Headache
, vol.40
, pp. 445-450
-
-
Silberstein, S.D.1
Mathew, N.2
Saper, J.3
-
52
-
-
0002661469
-
Botox for migraine: Double-blind, placebo-controlled, region-specific evaluation
-
Abstr.
-
Brin MF, Swope DM, O'Brien C, et al. 2000. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 20: 421 (Abstr.)
-
(2000)
Cephalalgia
, vol.20
, pp. 421
-
-
Brin, M.F.1
Swope, D.M.2
O'Brien, C.3
-
53
-
-
0038290443
-
Efficacy and safety of botulinum toxin type a (Botox®) in the prophylactic treatment of migraine
-
Abstr.
-
Barrientos N, Chana P. 2002. Efficacy and safety of botulinum toxin type A (Botox®) in the prophylactic treatment of migraine. Headache 42:452 (Abstr.)
-
(2002)
Headache
, vol.42
, pp. 452
-
-
Barrientos, N.1
Chana, P.2
-
54
-
-
0037952892
-
Single-site Botox injection for the elimination of migraine trigger points
-
Abstr.
-
Behmand RA, Tucker T, Guyuron B, et al. 2002. Single-site Botox injection for the elimination of migraine trigger points. Headache 42:403 (Abstr.)
-
(2002)
Headache
, vol.42
, pp. 403
-
-
Behmand, R.A.1
Tucker, T.2
Guyuron, B.3
-
55
-
-
0347335621
-
Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients
-
Abstr.
-
Relja MA, Klepac N. 2003. Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients. Neurology 60:A321 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Relja, M.A.1
Klepac, N.2
-
56
-
-
0000338266
-
Botulinum toxin a is an effective prophylactic therapy for migraines
-
Abstr.
-
Mauskop A, Basdeo R. 2000. Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalalgia 20:422 (Abstr.)
-
(2000)
Cephalalgia
, vol.20
, pp. 422
-
-
Mauskop, A.1
Basdeo, R.2
-
57
-
-
0000099456
-
Botulinum toxin type a in the treatment of headache syndromes: A clinical report on 79 patients
-
Abstr.
-
Smuts JA, Barnard PW. 2000. Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 20:332 (Abstr.)
-
(2000)
Cephalalgia
, vol.20
, pp. 332
-
-
Smuts, J.A.1
Barnard, P.W.2
-
58
-
-
0038211994
-
"Disease modification" in chronic migraine with botulinum toxin type A: Long-term experience
-
Abstr.
-
Mathew NT, Kailasam J, Meadors L. 2002. "Disease modification" in chronic migraine with botulinum toxin type A: long-term experience. Headache 42:454-( Abstr.)
-
(2002)
Headache
, vol.42
, pp. 454
-
-
Mathew, N.T.1
Kailasam, J.2
Meadors, L.3
-
59
-
-
1542276450
-
Botulinum toxin a for refractory chronic daily headache
-
Abstr.
-
Robbins LD. 2001. Botulinum toxin A for refractory chronic daily headache. Cephalalgia 21:465 (Abstr.)
-
(2001)
Cephalalgia
, vol.21
, pp. 465
-
-
Robbins, L.D.1
-
60
-
-
1542306590
-
Botulinum toxin a for chronic daily headache: A 60-patient, randomized, placebo-controlled, parallel design study
-
Abstr.
-
Ondo WG, Derman HS. 2002. Botulinum toxin A for chronic daily headache: a 60-patient, randomized, placebo-controlled, parallel design study. Headache 42:431 (Abstr.)
-
(2002)
Headache
, vol.42
, pp. 431
-
-
Ondo, W.G.1
Derman, H.S.2
-
61
-
-
0023857464
-
Antitoxin reduces botulinum side effects
-
Scott AB. 1988. Antitoxin reduces botulinum side effects. Eye 2:29-32
-
(1988)
Eye
, vol.2
, pp. 29-32
-
-
Scott, A.B.1
-
62
-
-
0018799297
-
Disorders of neuromuscular transmission caused by drugs
-
Argov Z, Mastaglia FL. 1979. Disorders of neuromuscular transmission caused by drugs. N. Engl J. Med. 301:409-13
-
(1979)
N. Engl J. Med.
, vol.301
, pp. 409-413
-
-
Argov, Z.1
Mastaglia, F.L.2
-
63
-
-
85031061407
-
Botulinum toxin type B for migraine prophylaxis: A 4-month open-label prospective outcome study
-
Abstr.
-
Lake AE, Saper JR. 2003. Botulinum toxin type B for migraine prophylaxis: a 4-month open-label prospective outcome study. Neurology 60:A322 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Lake, A.E.1
Saper, J.R.2
-
64
-
-
0011140951
-
Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches
-
Abstr.
-
Opida C. 2002. Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches. J. Pain 3:10 (Abstr.)
-
(2002)
J. Pain
, vol.3
, pp. 10
-
-
Opida, C.1
-
65
-
-
26144480416
-
Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache
-
Abstr.
-
Gwynn MW, Baker T, English J. 2003. Double-blind, placebo-controlled study of botulinum toxin B for the treatment of chronic headache. Neurology 60:A322 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Gwynn, M.W.1
Baker, T.2
English, J.3
-
67
-
-
0030710582
-
Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
-
Langtry HD, Gillis JC, Davis R. 1997. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54:752-73
-
(1997)
Drugs
, vol.54
, pp. 752-773
-
-
Langtry, H.D.1
Gillis, J.C.2
Davis, R.3
-
69
-
-
0032171131
-
Use of topiramate, a new antiepileptic as a mood stabilizer
-
Marcotte D. 1998. Use of topiramate, a new antiepileptic as a mood stabilizer. J. Affect. Disord. 50:245-51
-
(1998)
J. Affect. Disord.
, vol.50
, pp. 245-251
-
-
Marcotte, D.1
-
70
-
-
1542366353
-
Efficacy and safety of topiramate in migraine prevention: A dose ranging placebo-controlled, double blind, multi-centered trial
-
In press
-
Silberstein SD, Neto W, Jacobs D, et al. 2003. Efficacy and safety of topiramate in migraine prevention: a dose ranging placebo-controlled, double blind, multi-centered trial. Cephalalgia In press
-
(2003)
Cephalalgia
-
-
Silberstein, S.D.1
Neto, W.2
Jacobs, D.3
-
71
-
-
0035654407
-
Antiepileptic drugs: How they work in headache
-
Cutrer FM. 2001. Antiepileptic drugs: how they work in headache. Headache 41(Suppl. 1):S3-S10
-
(2001)
Headache
, vol.41
, Issue.1 SUPPL.
-
-
Cutrer, F.M.1
-
72
-
-
0344809172
-
Topiramate inhibits trigeminovascular traffic in the cat: A possible locus of action in the prevention of migraine
-
Abstr.
-
Storer RJ, Goadsby PJ. 2003. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 60:A238 (Abstr.)
-
(2003)
Neurology
, vol.60
-
-
Storer, R.J.1
Goadsby, P.J.2
-
73
-
-
0036781473
-
Topiramate: A case series study in migraine prophylaxis
-
Young WB, Hopkins MM, Shechter AL, et al. 2002. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22:659-63
-
(2002)
Cephalalgia
, vol.22
, pp. 659-663
-
-
Young, W.B.1
Hopkins, M.M.2
Shechter, A.L.3
-
74
-
-
0036754793
-
Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate
-
Mathew NT, Kailasam J, Meadors L. 2002. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42:796-803
-
(2002)
Headache
, vol.42
, pp. 796-803
-
-
Mathew, N.T.1
Kailasam, J.2
Meadors, L.3
-
75
-
-
0344809171
-
Topiramate in the prevention of migraine headache: A randomized, double-blind, placebo-controlled, multiple-dose study
-
In press
-
Silberstein SD, Bhattacharaya S, Neto W, et al., for the MIGR-001 Study Group. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. Cephalagia In press
-
(2003)
Cephalagia
-
-
Silberstein, S.D.1
Bhattacharaya, S.2
Neto, W.3
-
76
-
-
0038762226
-
Topiramate in the prevention of migraine headache: A randomized, double-blind, placebo-controlled parallel study (MIGR-002)
-
Abstr.
-
Brandes JL, Jacobs D, Neto W, et al. 2003. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled parallel study (MIGR-002). Neurology 60(Suppl. 1):A238 (Abstr.)
-
(2003)
Neurology
, vol.60
, Issue.1 SUPPL.
-
-
Brandes, J.L.1
Jacobs, D.2
Neto, W.3
-
77
-
-
0035651241
-
Topiramate in migraine prevention: A double-blind, placebo-controlled study
-
Storey JR, Calder CS, Hart DE, et al. 2001. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41:968-75
-
(2001)
Headache
, vol.41
, pp. 968-975
-
-
Storey, J.R.1
Calder, C.S.2
Hart, D.E.3
-
78
-
-
0036754584
-
Efficacy of topiramate in migraine prophylaxis: A retrospective chart analysis
-
Von Seggern RL, Mannix LK, Adelman JU. 2002. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 42:804-9
-
(2002)
Headache
, vol.42
, pp. 804-809
-
-
Von Seggern, R.L.1
Mannix, L.K.2
Adelman, J.U.3
-
79
-
-
0029164712
-
ACE inhibitors for prophylaxis of migraine headaches
-
Bender WI. 1995. ACE inhibitors for prophylaxis of migraine headaches. Headache 35:470-71
-
(1995)
Headache
, vol.35
, pp. 470-471
-
-
Bender, W.I.1
-
80
-
-
0035814597
-
Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo-controlled, crossover study
-
Schrader H, Stovner LJ, Helde G, et al. 2001. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. Br. J. Med. Psychol. 3222:19-22
-
(2001)
Br. J. Med. Psychol.
, vol.3222
, pp. 19-22
-
-
Schrader, H.1
Stovner, L.J.2
Helde, G.3
-
81
-
-
0037218941
-
Prophylactic treatment of migraine with an angiotensin II receptor blocker a randomized controlled trial
-
Tronvik E, Stovner LJ, Helde G, et al. 2003. Prophylactic treatment of migraine with an angiotensin II receptor blocker a randomized controlled trial. JAMA 289:65-69
-
(2003)
JAMA
, vol.289
, pp. 65-69
-
-
Tronvik, E.1
Stovner, L.J.2
Helde, G.3
-
82
-
-
0033796377
-
1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats
-
1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-86
-
(2000)
Stroke
, vol.31
, pp. 2478-2486
-
-
Nishimura, Y.1
Ito, T.2
Saavedra, J.M.3
-
83
-
-
0027156129
-
Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats
-
Mendelsohn FA, Jenkins TA, Berkovic SF. 1993. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613:221-29
-
(1993)
Brain Res.
, vol.613
, pp. 221-229
-
-
Mendelsohn, F.A.1
Jenkins, T.A.2
Berkovic, S.F.3
-
84
-
-
0036322902
-
Locally synthesized angiotensin modulates pineal melatonin generation
-
Baltatu O, Afeche SC, Jose-dos Santos SH, et al. 2002. Locally synthesized angiotensin modulates pineal melatonin generation. J. Neurochem. 80:328-34
-
(2002)
J. Neurochem.
, vol.80
, pp. 328-334
-
-
Baltatu, O.1
Afeche, S.C.2
Jose-Dos Santos, S.H.3
-
85
-
-
0036009156
-
Nuclear factor-κB as a molecular target for migraine therapy
-
Reuter U, Chiarugi A, Bolay H, et al. 2002. Nuclear factor-κB as a molecular target for migraine therapy. Ann. Neurol. 51:507-16
-
(2002)
Ann. Neurol.
, vol.51
, pp. 507-516
-
-
Reuter, U.1
Chiarugi, A.2
Bolay, H.3
|